BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31519161)

  • 1. Shaping the regulation of the p53 mRNA tumour suppressor: the co-evolution of genetic signatures.
    Karakostis K; Fåhraeus R
    BMC Cancer; 2019 Sep; 19(1):915. PubMed ID: 31519161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mRNA and p53 Protein Structures Have Evolved Independently to Interact with MDM2.
    Karakostis K; Ponnuswamy A; Fusée LT; Bailly X; Laguerre L; Worall E; Vojtesek B; Nylander K; Fåhraeus R
    Mol Biol Evol; 2016 May; 33(5):1280-92. PubMed ID: 26823446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 mRNA controls p53 activity by managing Mdm2 functions.
    Candeias MM; Malbert-Colas L; Powell DJ; Daskalogianni C; Maslon MM; Naski N; Bourougaa K; Calvo F; Fåhraeus R
    Nat Cell Biol; 2008 Sep; 10(9):1098-105. PubMed ID: 19160491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of Daxx by ATM contributes to DNA damage-induced p53 activation.
    Tang J; Agrawal T; Cheng Q; Qu L; Brewer MD; Chen J; Yang X
    PLoS One; 2013; 8(2):e55813. PubMed ID: 23405218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single synonymous mutation determines the phosphorylation and stability of the nascent protein.
    Karakostis K; Vadivel Gnanasundram S; López I; Thermou A; Wang L; Nylander K; Olivares-Illana V; Fåhraeus R
    J Mol Cell Biol; 2019 Mar; 11(3):187-199. PubMed ID: 30252118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The p53 mRNA-Mdm2 interaction.
    Naski N; Gajjar M; Bourougaa K; Malbert-Colas L; Fåhraeus R; Candeias MM
    Cell Cycle; 2009 Jan; 8(1):31-4. PubMed ID: 19106616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2's dual mRNA binding domains co-ordinate its oncogenic and tumour suppressor activities.
    Gnanasundram SV; Malbert-Colas L; Chen S; Fusée L; Daskalogianni C; Muller P; Salomao N; Fåhraeus R
    Nucleic Acids Res; 2020 Jul; 48(12):6775-6787. PubMed ID: 32453417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53-mediated control of gene expression via mRNA translation during Endoplasmic Reticulum stress.
    López I; Tournillon AS; Nylander K; Fåhraeus R
    Cell Cycle; 2015; 14(21):3373-8. PubMed ID: 26397130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoactivation of the MDM2 E3 ligase by intramolecular interaction.
    Cheng Q; Song T; Chen L; Chen J
    Mol Cell Biol; 2014 Aug; 34(15):2800-10. PubMed ID: 24842904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDMX folds the nascent p53 mRNA following activation by the ATM kinase.
    Malbert-Colas L; Ponnuswamy A; Olivares-Illana V; Tournillon AS; Naski N; Fåhraeus R
    Mol Cell; 2014 May; 54(3):500-11. PubMed ID: 24813712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DNA damage sensor ATM kinase interacts with the p53 mRNA and guides the DNA damage response pathway.
    Karakostis K; Malbert-Colas L; Thermou A; Vojtesek B; Fåhraeus R
    Mol Cancer; 2024 Jan; 23(1):21. PubMed ID: 38263180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage.
    Gajjar M; Candeias MM; Malbert-Colas L; Mazars A; Fujita J; Olivares-Illana V; Fåhraeus R
    Cancer Cell; 2012 Jan; 21(1):25-35. PubMed ID: 22264786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
    Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
    Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
    Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
    FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The regulation of MDM2 oncogene and its impact on human cancers.
    Zhao Y; Yu H; Hu W
    Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):180-9. PubMed ID: 24389645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
    Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
    J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Elephant Evolved p53 Isoforms that Escape MDM2-Mediated Repression and Cancer.
    Padariya M; Jooste ML; Hupp T; Fåhraeus R; Vojtesek B; Vollrath F; Kalathiya U; Karakostis K
    Mol Biol Evol; 2022 Jul; 39(7):. PubMed ID: 35792674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of the MDM2-p53 pathway by the ubiquitin ligase HERC2.
    García-Cano J; Sánchez-Tena S; Sala-Gaston J; Figueras A; Viñals F; Bartrons R; Ventura F; Rosa JL
    Mol Oncol; 2020 Jan; 14(1):69-86. PubMed ID: 31665549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition.
    Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW
    Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
    Liu WL; Midgley C; Stephen C; Saville M; Lane DP
    J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.